Pharma wants Australia's A$1.86 billion price cut bill to be passed this month
This article was originally published in Scrip
Executive Summary
Dr Brendan Shaw, chief executive of the R&D industry association Medicines Australia, told Scrip that he hopes that Australia's medicine bill – which targets savings of A$1.86 billion (US$1.86 billion) over five years - will be approved this month because one of its key provisions, namely the disclosure of the prices of the less innovative drugs in the F2 formulary, is expected to start on 1 December.